On October 9, 2025, IceCure Medical Ltd. announced that members of its management team, including CEO Eyal Shamir, will participate in Maxim's Growth Summit. The summit is scheduled to take place in New York City on October 22 and 23, 2025. This event provides an opportunity for IceCure to engage with institutional investors in one-on-one meetings.
During these meetings, the management team will provide an overview of the company, highlighting its latest regulatory and commercial milestones in the U.S. and global markets. A key focus will be the recent U.S. Food and Drug Administration (FDA) marketing authorization for the ProSense® cryoablation system. This authorization was granted on October 3, 2025, for the local treatment of early-stage, low-risk breast cancer in patients aged 70 and over.
The FDA marketing authorization for ProSense® is a significant development, positioning the system as the first new innovation in decades for this patient population and potentially setting a new standard of care. The Maxim Growth Summit will allow IceCure to communicate the implications of this approval and its commercialization plans directly to a targeted investor audience.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.